Skip to main content

ADVERTISEMENT

Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
11/17/2021
Dr Jennings provides a meeting recap from the AHA Scientific Sessions 2021, highlighting noteworthy research findings on heart failure drugs.
Dr Jennings provides a meeting recap from the AHA Scientific Sessions 2021, highlighting noteworthy research findings on heart failure drugs.
Dr Jennings provides a meeting...
11/17/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
07/07/2022
Dr Jennings discusses new data showing empagliflozin's potential for effectively treating patients with acute decompensated heart failure.
Dr Jennings discusses new data showing empagliflozin's potential for effectively treating patients with acute decompensated heart failure.
Dr Jennings discusses new data...
07/07/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
04/21/2023
Dr Jennings shares new recommendations issued by the American College of Cardiology related to treating patients with heart failure with a preserved ejection fraction.
Dr Jennings shares new recommendations issued by the American College of Cardiology related to treating patients with heart failure with a preserved ejection fraction.
Dr Jennings shares new...
04/21/2023
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
04/09/2024
In this installment of Talking Therapeutics, Dr Jennings discusses the risks associated with combining selective serotonin inhibitors (SSRIs) and blood thinners.
In this installment of Talking Therapeutics, Dr Jennings discusses the risks associated with combining selective serotonin inhibitors (SSRIs) and blood thinners.
In this installment of Talking...
04/09/2024
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
03/10/2021
In this week’s column, Douglas Jennings, PharmD, looks at the latest updates on how heart failure is classified, and explores a novel treatment option for patients with heart failure with preserved ejection fraction.
In this week’s column, Douglas Jennings, PharmD, looks at the latest updates on how heart failure is classified, and explores a novel treatment option for patients with heart failure with preserved ejection fraction.
In this week’s column, Douglas...
03/10/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
02/02/2022
In this week's edition of Talking Therapeutics, Dr Jennings reviews data regarding the appropriate and safe use of dronedarone in patients who received atrial fibrillation ablation.
In this week's edition of Talking Therapeutics, Dr Jennings reviews data regarding the appropriate and safe use of dronedarone in patients who received atrial fibrillation ablation.
In this week's edition of...
02/02/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
02/16/2022
In the newest installment of Talking Therapeutics, Dr Jennings highlights extended post-procedure anticoagulation, as well as new research on acetaminophen's impact on blood pressure.
In the newest installment of Talking Therapeutics, Dr Jennings highlights extended post-procedure anticoagulation, as well as new research on acetaminophen's impact on blood pressure.
In the newest installment of...
02/16/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
08/01/2023
Dr Jennings discusses research showing a combination of rosuvastatin and ezetimibe could decrease the incidence of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease who received percutaneous coronary...
Dr Jennings discusses research showing a combination of rosuvastatin and ezetimibe could decrease the incidence of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease who received percutaneous coronary...
Dr Jennings discusses research...
08/01/2023
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
02/02/2023
In this week's installment of Talking Therapeutics, Dr Jennings discusses a study comparing the efficacy of 2 loop diuretics for patients with heart failure.
In this week's installment of Talking Therapeutics, Dr Jennings discusses a study comparing the efficacy of 2 loop diuretics for patients with heart failure.
In this week's installment of...
02/02/2023
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
09/01/2021
Reviewing the latest science from major medical meetings has become a recurring theme of Talking Therapeutics. This week, Dr Jennings reviews research presented at the European Society of Cardiology meeting.
Reviewing the latest science from major medical meetings has become a recurring theme of Talking Therapeutics. This week, Dr Jennings reviews research presented at the European Society of Cardiology meeting.
Reviewing the latest science...
09/01/2021
Pharmacy Learning Network